FDA finds control lapses at Catalent plant being sold to Novo

U.S. drug regulators in November found quality control lapses at the Bloomington, Indiana factory of contract drug manufacturer Catalent (CTLT.N), opens new tab, including discovery of a "pest" on the manufacturing line, according to an inspection report.